T-cell lymphoma
T-cell lymphoma | |
---|---|
stem cell transplant |
T-cell lymphoma is a rare form of cancerous
T-cell lymphoma is categorized under
The prognosis and treatment of T-cell lymphoma can vary drastically based on the specific type of lymphoma and its growth patterns. Due to their rarity and high variability between the different subtypes, the prognosis of T-cell lymphoma is significantly worse than other Non-Hodgkin lymphoma.
Types
There are many types and variations of T-cell lymphoma, each with vastly different symptoms, survival, and prognosis. The classification of T-cell lymphoma has been difficult to accomplish due to the lack of understanding of their biology.[4] Most classifications are basic with many still under the title of ‘provisional categories’ in the World Health Organization Classification of disease.[5]
Common
- Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS): Most common type of Peripheral T-cell lymphoma (PTCL), comprising subtypes which cannot be classified as either nodal, extra-nodal, or leukemic[citation needed]
- Angioimmunoblastic T-cell lymphoma (AITL): Aggressive form of T-cell lymphoma.[citation needed]
- Anaplastic large cell lymphoma (ALCL): ALCL has four distinct types:[citation needed]
- ALK-positive anaplastic large cell lymphoma: an aggressive, systemic ALCL that strongly expresses anaplastic lymphoma kinase, i.e. ALK.
- ALK-negative anaplastic large cell lymphoma: an aggressive, systemic ALCL that does not express ALK.
- Primary cutaneous anaplastic large cell lymphoma: a less aggressive ALCL that commonly presents as skin tumors.
- breast implants.
- Adult T-cell leukemia/lymphoma (ATL): Aggressive T-cell lymphoma, associated with RNA retrovirus, human T-cell leukemia virus type-1 (HTLV1)[citation needed]
- Extranodal NK/T-cell lymphoma, nasal type (ENKTL): Aggressive T-cell lymphoma, usually associated with Epstein–Barr virus (EBV)[citation needed]
- Cutaneous T-cell lymphoma (CTCL): can be indolent or aggressive[citation needed]
- Mycosis fungoides
- Sézary syndrome
Rare
- Subcutaneous panniculitis-like T-cell lymphoma (SPTCL):[citation needed]
- Cutaneous gamma-delta T-cell lymphoma (CGD-TCL)
- Systemic Epstein–Barr virus-positive T-Cell Lymphoproliferative Disorders of Childhood(EBVTCLD): A very aggressive group with association with Epstein–Barr virus (EBV)
- Primary intestinal T-cell lymphomas
- Hepatosplenic T-cell lymphoma (HSTCL)
Symptoms and signs
Differences in T-cell lymphoma subtypes extend to the clinical characteristics and symptoms of the disease with each varying drastically. As a result, there is almost no universally known symptom that can be applied to all T-cell lymphoma subtypes.[4]
The hemophagocytic syndrome (HPS)
Swollen lymph nodes
T-cell lymphoma which develops from the lymph nodes commonly causes symptoms as such swollen lymph nodes.[6] The swelling normally will not cause any pain and can be felt or seen as lumps on the surface of the skin. Nodal T-cell lymphoma subtypes such as peripheral T-cell lymphoma will often develop this symptom.[citation needed]
Skin infections
T-cell lymphoma can cause
Cause
Although there is no definitive cause for most T-cell lymphoma subtypes, a series of risk factors have been linked and associated with the increased likelihood of contracting the disease.
Risk factors
Family history: A family history of
Autoimmune conditions: Autoimmune conditions are commonly considered as a risk factor that has been associated with non-Hodgkin lymphomas, with
Organ transplants and immunosuppressant:
Infectious Agents: Several infectious agents have been linked to a higher risk of T-cell lymphoma by providing a compromised immune function allowing the establishment of lymphomas. Of these
Epstein–Barr virus is a largely common virus with more than 90% of individuals exposed to the virus in their lifetime. EBV has been consistently associated with many lymphoproliferation disorders, of these EBV-associated T-cell lymphomas include Epstein–Barr virus–associated lymphoproliferative diseases, angioimmunoblastic T-cell lymphoma (AITL), extranodal NK/T-cell lymphoma, nasal type, and Peripheral T-cell lymphoma not otherwise specified (PTCL, NOS).[8]
The
Diagnosis
The diagnosis of T-cell lymphoma varies largely between the subtypes. Some subtypes like anaplastic large-cell lymphoma have an exceptional diagnostic rate however,
Treatment
Treatment for T-cell lymphoma varies widely due to the large variability in the subtypes. Due to the lack of research performed in understanding the nature of T-cell lymphoma pathogenesis, a majority of cases will often have poor outcomes for the treatment or will relapse.[3] However, new research into new therapy methods have been made to help reduce the mortality rates and risk of relapse.[10][2]
Chemotherapy
Radiotherapy
Stem cell transplant
Stem Cell Transplants are a common method of treatment which can either be used in conjunction with chemotherapy to improve remission and effectiveness or it can be used with relapsed lymphoma patients.
Allogenic stem cell transplants are mainly used when the patient lacks adequate healthy stem cells for an autologous stem cell transplant or has relapsed after prior autologous stem cell transplant treatments.
Monoclonal antibodies
Monoclonal antibodies (mAb) utilizes
Nucleoside analogs
Other
Other non-tradition or new treatment options include:
Epidemiology
While the incidence of Non-Hodgkin's lymphoma has plateaued, the rate of T-cell lymphomas has gradually increased over the past few years. However, due to the low frequency and lack of research performed on the disease, the number of cases is relatively underrepresented compared to other non-Hodgkin lymphomas.[3]
Cases are more common in those of Native American descent followed by Caucasian ancestry,[2] however, the epidemiology can vary greatly between the different subtypes. The incidences[spelling?] of T-cell lymphoma are slightly higher in men than in women in all categories of race[6] with cases increasing in frequency with age for most subtypes.[2]
In Asia, T/NK-cell
See also
References
- ^ a b c d Quesenberry, Peter J.; Castillo, Jorge J. (2013). Non-Hodgkin Lymphoma Prognostic Factors and Targets. NY: Humana Press.
- ^ a b c d e f g h i j k l m n o p q Foss, Francine (2013). T-cell Lymphomas. Totowa, NJ: Humana Press.
- ^ a b c d e f g Querfeld, Christiane; Zain, Jasmine; Rosen, Steven T (2019). T-Cell and NK-Cell Lymphomas From Biology to Novel Therapies. Cham: Springer International Publishing.
- ^ PMID 26250731.
- ^ a b World Health Organization. "International Classification of Diseases 11th Revision". World Health Organization. Retrieved 5 October 2020.
- ^ ISBN 978-1-62703-407-4.
- S2CID 44302140.
- ^ a b c d e Evens, Andrew M.; Blum, Kristie A. (2015). Non-Hodgkin Lymphoma Pathology, Imaging, and Current Therapy. Cham: Springer International Publishing.
- ISBN 978-4-431-56523-9.
- ^ PMID 34661151.
- ISBN 978-1-118-66231-1.